Coeptis Therapeutics, Inc. (COEP)
USD 9.75
(2.85%)
USD 9.75
(2.85%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.75 Million USD | 20.72% |
| 2022 | 3.11 Million USD | -29.5% |
| 2021 | 4.41 Million USD | -18.9% |
| 2020 | 5.44 Million USD | 3392.95% |
| 2019 | 155.85 Thousand USD | 151.08% |
| 2018 | 62.07 Thousand USD | 0.0% |
| 2005 | 705.21 Thousand USD | 126.8% |
| 2004 | 310.93 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.03 Million USD | 34.01% |
| 2024 Q2 | 4.5 Million USD | -10.46% |
| 2023 FY | 3.75 Million USD | 20.72% |
| 2023 Q3 | 2.15 Million USD | -53.73% |
| 2023 Q4 | 3.75 Million USD | 74.01% |
| 2023 Q2 | 4.66 Million USD | 0.21% |
| 2023 Q1 | 4.65 Million USD | 49.61% |
| 2022 Q3 | 4.52 Million USD | 1.31% |
| 2022 FY | 3.11 Million USD | -29.5% |
| 2022 Q4 | 3.11 Million USD | -31.16% |
| 2022 Q1 | 4.41 Million USD | -0.08% |
| 2022 Q2 | 4.46 Million USD | 1.16% |
| 2021 Q1 | 8.76 Million USD | 17405.72% |
| 2021 FY | 4.41 Million USD | -18.9% |
| 2021 Q4 | 4.41 Million USD | -28.32% |
| 2021 Q3 | 6.15 Million USD | -40.9% |
| 2021 Q2 | 10.42 Million USD | 18.85% |
| 2020 FY | 5.44 Million USD | 3392.95% |
| 2020 Q4 | 50.09 Thousand USD | 30.3% |
| 2020 Q3 | 38.44 Thousand USD | 0.0% |
| 2019 FY | 155.85 Thousand USD | 151.08% |
| 2018 FY | 62.07 Thousand USD | 0.0% |
| 2005 FY | 705.21 Thousand USD | 126.8% |
| 2005 Q4 | 705.21 Thousand USD | 59.01% |
| 2005 Q2 | 434.8 Thousand USD | 53.13% |
| 2005 Q3 | 443.49 Thousand USD | 2.0% |
| 2005 Q1 | 283.93 Thousand USD | -8.68% |
| 2004 Q3 | 310.93 Thousand USD | 0.0% |
| 2004 Q4 | 310.93 Thousand USD | 0.0% |
| 2004 FY | 310.93 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -13595.64% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 60.309% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.816% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -364.534% |
| Rebus Holdings, Inc. | 5.24 Million USD | 28.326% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.634% |
| Qrons Inc. | 1.48 Million USD | -152.374% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -206.401% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 94.985% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8305.954% |
| Skye Bioscience, Inc. | 14.07 Million USD | 73.301% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 92.952% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 60.79% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -791.226% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.492% |
| Intellipharmaceutics International Inc. | 12 Million USD | 68.713% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 2.448% |
| Mesoblast Limited | 188.44 Million USD | 98.006% |
| Marizyme, Inc. | 26.67 Million USD | 85.916% |
| Genus plc | 485 Million USD | 99.225% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 35.695% |
| Pharming Group N.V. | 244.07 Million USD | 98.461% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -86.91% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -49.31% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 1.128% |
| ContraFect Corporation | 32.53 Million USD | 88.451% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -89.629% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 1.842% |
| IMV Inc. | 37.93 Million USD | 90.095% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 68.101% |
| MultiCell Technologies, Inc. | 1617.67 USD | -232155.343% |
| ONE Bio Corp. | 27.49 Million USD | 86.336% |
| Accustem Sciences Inc. | 1.07 Million USD | -248.127% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.147% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -77.636% |
| Q BioMed Inc. | 8.13 Million USD | 53.804% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.47% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 26.99% |
| Biomind Labs Inc. | 1.49 Million USD | -150.707% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.835% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 58.449% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 79.585% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -162.029% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2544.094% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1768.138% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 34.611% |
| GB Sciences, Inc. | 5.41 Million USD | 30.649% |
| Alpha Cognition Inc. | 7.16 Million USD | 47.561% |
| HST Global, Inc. | 593.59 Thousand USD | -532.946% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -198.376% |
| Halberd Corporation | 728.71 Thousand USD | -415.579% |
| Enzolytics Inc. | 365.26 Million USD | 98.971% |
| Agentix Corp. | 2.51 Million USD | -49.653% |
| Resverlogix Corp. | 67.39 Million USD | 94.425% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -347.953% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.156% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -119.202% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 84.817% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 68.436% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -2.509% |
| AVAX Technologies, Inc. | 3.99 Million USD | 5.925% |
| Zenith Capital Corp. | 27.56 Thousand USD | -13528.079% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.717% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1474.298% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -0.611% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -451.842% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -38.555% |
| Kadimastem Ltd | 3.5 Million USD | -7.197% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5513.598% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.525% |
| BioStem Technologies, Inc. | 15.9 Million USD | 76.377% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -708.507% |
| LadRx Corporation | 2.2 Million USD | -70.737% |
| Cell Source, Inc. | 15.8 Million USD | 76.231% |
| Regen BioPharma, Inc. | 5.45 Million USD | 31.158% |
| Regen BioPharma, Inc. | 5.45 Million USD | 31.158% |
| NovAccess Global Inc. | 7.86 Million USD | 52.204% |
| Affymax, Inc. | 8.87 Million USD | 57.647% |
| Itoco Inc. | 1.65 Million USD | -127.271% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -83.135% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 37.888% |
| Mobile Lads Corp. | 1.31 Million USD | -186.04% |
| CytoDyn Inc. | 127.89 Million USD | 97.062% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8888.552% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -139.861% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 65.984% |
| SYBLEU INC | 681.41 Thousand USD | -451.373% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 38.427% |
| International Stem Cell Corporation | 5.27 Million USD | 28.802% |
| Bioxytran, Inc. | 3.24 Million USD | -15.622% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -500.363% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 18.626% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 90.835% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 83.125% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -85.502% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 31.414% |
| Neutra Corp. | 973.52 Thousand USD | -285.928% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.051% |
| PureTech Health plc | 125.58 Million USD | 97.008% |
| IXICO plc | 1.9 Million USD | -97.713% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 81.698% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.364% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Cellectis S.A. | 249.36 Million USD | 98.493% |